Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Programmed cell death 1 (PDCD1; PD-1; CD279)

Mouse studies suggest PD-1 inhibitors could help improve the efficacy of dendritic cell (DC)-activating cancer vaccines. In a mouse model of melanoma, an experimental, DC-activating cancer vaccine plus an anti-PD-1 mAb caused tumor regression, whereas vaccine alone only inhibited tumor growth. Next steps could include evaluating the combination in a clinical trial.
Bristol-Myers Squibb Co. and Ono Pharmaceutical Co. Ltd. have the PD-1 antibody nivolumab under FDA review to treat advanced melanoma and non-small cell lung cancer (NSCLC).
Merck & Co. Inc. has the PD-1 antibody MK-3475 (formerly lambrolizumab) under FDA review to treat advanced melanoma.
At least four other companies have antibodies against PD-1 in Phase II or earlier testing to treat cancers.

SciBX 7(24); doi:10.1038/scibx.2014.701
Published online June 19, 2014

Patent and licensing status unavailable

Fu, J. et al. Cancer Res.;
published online May 8, 2014;
doi:10.1158/0008-5472.CAN-13-2685
Contact: Young J. Kim, The Johns Hopkins University School of Medicine, Baltimore, Md.
e-mail:
ykim76@jhmi.edu